HDV+HBV hepatitis reactivation due to immunossuppressive therapy for hematological malignancies – an increasingly complex challenge

Background Hepatitis B virus reactivation (HBV-R) is becoming an increasingly concerning issue as monoclonal antibody therapy has become widely used for chronic lymphoproliferations. HBV-R can also occur in HBsAg negative patients who have only HBcAb positive (occult HBV infection). We present a non-consecutive HBV-R case series report. Our series consisted of both HBsAg positive patients and patients with occult HBV infection, who received monoclonal antibody therapy. We present the most important demographic, clinical and immune-virological features of HBV-R in these patients.